THE COURSE OF NEURO-ENDOCRINE DIFFERENTIATION IN PROSTATIC CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY TESTING CHROMOGRANIN-A AS AN ENDOCRINE MARKER
THE COURSE OF NEURO-ENDOCRINE DIFFERENTIATION IN PROSTATIC CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY TESTING CHROMOGRANIN-A AS AN ENDOCRINE MARKER
复制标题
DOI：
10.1016/s0344-0338(89)80016-0
复制
发表时间：
1989-09-01
影响因子：
2.8
通讯作者：
GRIMELIUS, L
中科院分区：
文献类型：
--
作者：
ABRAHAMSSON, PA;FALKMER, S;GRIMELIUS, L
为了进一步了解前列腺癌神经内分泌（NE）分化的发病机制，我们研究了前列腺癌病程中肿瘤进展过程中NE表现的发生率。这种后续行动采取了半定量评估的形式NE细胞癌的手段重复活检，在几年的时间间隔，相关的结果与传统的前列腺肿瘤的组织病理学分级。用嗜铬粒蛋白A（ChrA）免疫反应和Grimelius银染技术检测NE细胞。在所有25种癌中，观察到Gimelius银染色结果与ChrA免疫反应性基础上获得的结果之间存在很强的相关性。此外，细胞免疫反应的抗血清对ChrA发现在几乎所有的部分从24例增生的前列腺被发现几乎总是嗜银。大多数的25个癌进行了显着的肿瘤进展，而NE细胞的数量伴随着增加。在我们用类固醇治疗的前列腺癌系列中，NE分化程度和肿瘤进展之间可以说明明确的关系，即，前列腺癌的间变性越强，其NE细胞越多。ChrA可被认为是前列腺增生和前列腺癌中NE细胞的敏感标志物。NE分化随时间的增加与前列腺癌的组织病理学去分化程度的显著增加相关，并且发现这些肿瘤的转移结节中的肿瘤细胞显示出与原发肿瘤相同的NE分化的免疫组织化学特征，支持NE细胞是真正的肿瘤细胞，其来源于具有多重分化模式的共同前体干细胞的观点。
To gain further insight into the pathogenetic aspects of neuroendocrine (NE) differentiation in prostatic carcinoma, the incidence of NE manifestations was studied during tumour progression in the course of the disease. This follow-up took the form of semiquantitative assessment of the NE cells in carcinomas by means of repeat biopsies at intervals of a few years, correlating the findings with those of conventional histopathological grading of the prostatic tumours. Immunoreactivity to chromogranin A (ChrA) and the Grimelius silver-staining technique were used to detect NE cells. A strong correlation was observed in all the 25 carcinomas studied between the results obtained with the Gimelius silver-staining and those obtained on the basis of immunoreactivity to ChrA. In addition, cells immunoreactive to an antiserum against ChrA found in virtually all sections from 24 cases of hyperplastic prostatic glands were found to be almost invariably argyrophil. Most of the 25 carcinomas underwent marked tumour progression, while the number of NE cells concomitantly increased. An unequivocal relationship can be stated between the degree of NE differentiation and tumour progression in our series of prostatic carcinomas treated with steroids-i.e., the more anaplastic the prostatic carcinoma, the more numerous are its NE cells. ChrA may be considered to be a sensitive marker for NE cells both in hyperplasia and in prostatic carcinomas. The increased NE differentiation with time correlating with the marked increase in the degree of histopathological dedifferentiation of the prostatic carcinomas, and the fact that the neoplastic cells in the metastatic nodules of these tumours were found to demonstrate the same immunhistochemical characteristics of NE differentiation as the primary tumour, support the idea that NE cells are genuine neoplastic cell deriving from a common precursor stem cell with a pattern of multiple differentiation.